Skip to Main Content

Christopher Dvorak


Pediatric hematologist-oncologist
Bone marrow transplant specialist
Chief, Pediatric Allergy, Immunology and Bone Marrow Transplant Division
Sherlock Holmes enthusiast

Dr. Christopher Dvorak is a specialist in stem cell transplantation for children with immunodeficiencies, blood disorders and cancer. He is chief of the UCSF Pediatric Allergy, Immunology and Bone Marrow Transplantation (BMT) Division and director of the Pediatric Cellular Therapy Laboratory.

In his research, Dvorak studies ways to lower the incidence of relapse in patients who have stem cell transplants for childhood leukemia. He also investigates how to minimize BMT complications and how to improve outcomes after stem cell transplants for severe combined immunodeficiencies (genetic disorders in which infants lack normal immune function), often called SCID.

Dvorak earned his medical degree at Vanderbilt University School of Medicine. He completed a residency in pediatrics as well as a fellowship in pediatric hematology, oncology and BMT at Stanford Medicine. Prior to joining UCSF in 2007, he was a clinical instructor for Stanford Medicine in the pediatric stem cell transplantation division

Dvorak is a national co-leader of the Primary Immune Deficiency Treatment Consortium, and he leads the Cancer Control and Supportive Care Committee for the Children’s Oncology Group.

  • Education

    Vanderbilt University School of Medicine, 1998

  • Residencies

    Stanford Medicine, Pediatrics, 2001

  • Fellowships

    Stanford Medicine, Pediatric Hematology and Oncology, 2005

  • Board Certifications

    Pediatric Hematology-Oncology, American Board of Pediatrics

  • Academic Title


Bone marrow transplant is a complex procedure with significant risks. My passion is to make it so safe that anyone could have a successful transplant.

Where I see patients (2)

    Decorative Caduceus

    A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

    The cumulative incidence of Grade III-IV acute GVHD at Day 100 will be summarized by incidence curves. GVHD evaluations will be performed using standard criteria.37 Patients with graft rejection will be censored.


    More about this study
    Decorative Caduceus

    JSP191 Antibody Targeting Conditioning in SCID Patients

    The number of subjects experiencing dose limiting toxicities including adverse events and serious adverse events will be assessed.


    More about this study
    Decorative Caduceus

    Conditioning SCID Infants Diagnosed Early

    Humoral immune reconstitution by 2 years post HCT, defined by specific antibody response to tetanus toxoid. Criteria for evaluation of humoral immune response are the following: Donor T cell chimerism ≥50% B cell count ≥50 cells/m...


    More about this study
    Decorative Caduceus

    EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

    Patients will be monitored for adverse events related to the infusion of EBV CTLs


    More about this study
    See all clinical trials

    Learning never stops

    Our classroom and bedside classes help kids get credit and keep learning during treatment.

    See our school program